-
61.发明公开公开(公告)号：US20240216495A1
公开(公告)日：2024-07-04
申请号：US18446883
申请日：2023-08-09
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
CPC classification number: A61K39/08 , A61K9/19 , A61K2039/545
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
62.发明公开公开(公告)号：US20240181028A1
公开(公告)日：2024-06-06
申请号：US18513738
申请日：2023-11-20
Applicant: Pfizer Inc.
Inventor： Catherine Alex , Annaliesa Sybil Anderson , Bishwa Raj Bhetuwal , Zecheng Chen , Kaushik Dutta , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran , Abhishek Ravindra Vartak , YuYing Yang
CPC classification number: A61K39/092 , A61K47/646
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
公开(公告)号：US20230346903A1
公开(公告)日：2023-11-02
申请号：US18060779
申请日：2022-12-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , C07K16/1275 , C07K16/44 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20220401544A1
公开(公告)日：2022-12-22
申请号：US17764153
申请日：2020-09-24
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , John Lance Perez , Kathrin Ute Jansen , Paul Liberator , Cuiwen Tan , Thomas Richard Jones , Johannes Frederik Beeslaar , Judith Absalon , Jason Douglas Maguire , Shannon Lea Harris
IPC: A61K39/095 , A61P31/04 , A61K47/02
Abstract: NEW MATERIAL: Recombinant plasmid pTPGIF2 having a size of 4,660 base pairs and a structure obtained by inserting a DNA having a size of 52 base pairs and containing a sequence coding somatostatin into a BamHI incision site of a plasmid vector pTP70-1 capable or fusing a heteropeptide to a carboxy-terminal of a dihydrofolic acid reductase gene of E. coli. USE: Producton of fused protein containing somatostatin.
PREPARATION: A somatostatin gene is integrated into a plasmid vector pTP70-1. pTPGIF2 is kept in stable state when introduced into E. coli. C600 strain. The E. coli. C600 train containing pTPGIF2 is deposited in Fermentation Research institute as FERM BP-1577.-
65.发明申请公开(公告)号：US20220387576A1
公开(公告)日：2022-12-08
申请号：US17824295
申请日：2022-05-25
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran
Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
-
Patent Agency Ranking
公开(公告)号：US11472850B2
公开(公告)日：2022-10-18
申请号：US17060067
申请日：2020-09-30
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095 , A61K39/00
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20220184199A1
公开(公告)日：2022-06-16
申请号：US17601949
申请日：2020-04-06
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Isis Kanevsky , Farid Latif Khan , Charles Harold Jones , John Michael McLaughlin
IPC: A61K39/09
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
公开(公告)号：US20210145957A1
公开(公告)日：2021-05-20
申请号：US17161119
申请日：2021-01-28
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20210085773A1
公开(公告)日：2021-03-25
申请号：US17114802
申请日：2020-12-08
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/095 , A61K39/00 , C07K14/22 , A61K39/295 , A61K47/64 , A61K39/12 , A61K47/02 , A61K47/22 , A61K47/26
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US10829521B2
公开(公告)日：2020-11-10
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: A61K39/095 , C07K14/22 , A61K39/00
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
-
-
-
-
-
-
-
-
Search Results
78
records
(took 0.028 seconds)
